Introduction.The possible risk factors for chronic kidney disease in transplant recipients have n... more Introduction.The possible risk factors for chronic kidney disease in transplant recipients have not been thoroughly investigated after living-donor liver transplantation.Material and Methods.A retrospective cohort study of consecutive adults who underwent living-donor liver transplantation between May 2004 and October 2016, in a single center, was conducted. Kidney function was investigated successively for all the patients throughout the study period, with 12 months being the shortest follow-up. Postoperative renal dysfunction was defined in accordance with the Chronic Kidney Disease Epidemiology Collaboration criteria. The patients’ demographic data, preoperative and intraoperative parameters, and outcomes were recorded. A calcineurin inhibitor-based immunosuppressive regimen, either tacrolimus or cyclosporine, was used in all the patients.Results.Of the 413 patients included in the study, 33 (8%) who survived for ≥1 year experienced chronic kidney disease 1 year after living-dono...
Aim: To estimate the prevalence of New Onset Diabetes after Liver Transplantation (NODAT) and to ... more Aim: To estimate the prevalence of New Onset Diabetes after Liver Transplantation (NODAT) and to investigate the possible risk factors. Methods: This retrospective study comprises 213 patients subjected to living donor liver transplantation (LDLT). Patients’ data were collected from medical registry files for a period of two years after transplant. Results: Of the total 213 recipients, complete data for the whole study period were available for 164 recipients who were enrolled in this study. Fifty one 51 (31.1%) patients were already diabetic prior to transplantation. The prevalence of NODAT was 27.43% (31/113). Eight of NODAT cases (25.8%) were transient with recovery within 6-months period in 5/8 cases while the other 3 cases recovered in more than 6 months to a year. The only drug that showed statistically significant difference was tacrolimus (p=0.02). Interestingly, three pre-transplant diabetics (3/51, 5.9%) recovered after liver transplant with elimination of their anti-diabe...
Introduction.The possible risk factors for chronic kidney disease in transplant recipients have n... more Introduction.The possible risk factors for chronic kidney disease in transplant recipients have not been thoroughly investigated after living-donor liver transplantation.Material and Methods.A retrospective cohort study of consecutive adults who underwent living-donor liver transplantation between May 2004 and October 2016, in a single center, was conducted. Kidney function was investigated successively for all the patients throughout the study period, with 12 months being the shortest follow-up. Postoperative renal dysfunction was defined in accordance with the Chronic Kidney Disease Epidemiology Collaboration criteria. The patients’ demographic data, preoperative and intraoperative parameters, and outcomes were recorded. A calcineurin inhibitor-based immunosuppressive regimen, either tacrolimus or cyclosporine, was used in all the patients.Results.Of the 413 patients included in the study, 33 (8%) who survived for ≥1 year experienced chronic kidney disease 1 year after living-dono...
Aim: To estimate the prevalence of New Onset Diabetes after Liver Transplantation (NODAT) and to ... more Aim: To estimate the prevalence of New Onset Diabetes after Liver Transplantation (NODAT) and to investigate the possible risk factors. Methods: This retrospective study comprises 213 patients subjected to living donor liver transplantation (LDLT). Patients’ data were collected from medical registry files for a period of two years after transplant. Results: Of the total 213 recipients, complete data for the whole study period were available for 164 recipients who were enrolled in this study. Fifty one 51 (31.1%) patients were already diabetic prior to transplantation. The prevalence of NODAT was 27.43% (31/113). Eight of NODAT cases (25.8%) were transient with recovery within 6-months period in 5/8 cases while the other 3 cases recovered in more than 6 months to a year. The only drug that showed statistically significant difference was tacrolimus (p=0.02). Interestingly, three pre-transplant diabetics (3/51, 5.9%) recovered after liver transplant with elimination of their anti-diabe...
Uploads